Therapy Insight: management of hepatorenal syndrome

@article{Crdenas2006TherapyIM,
  title={Therapy Insight: management of hepatorenal syndrome},
  author={Andr{\'e}s C{\'a}rdenas and Pere Gin{\`e}s},
  journal={Nature Clinical Practice Gastroenterology \&Hepatology},
  year={2006},
  volume={3},
  pages={338-348}
}
  • A. Cárdenas, P. Ginès
  • Published 1 June 2006
  • Medicine
  • Nature Clinical Practice Gastroenterology &Hepatology
Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal failure, secondary to renal vasoconstriction in the absence of underlying kidney pathology. Extreme underfilling of the arterial circulation, caused by arterial vasodilation of the splanchnic circulation, activates vasoconstrictor systems, which lead to intense renal vasoconstriction and HRS. Factors predictive for the development of HRS include intense urinary sodium retention… 
Current Therapies for Hepatorenal Syndrome
TLDR
Hepatorenal syndrome prophylaxis is recommended in patients with spontaneous bacterial peritonitis, advanced cirrhosis and those with severe acute alcoholic hepatitis, especially in those who have a rapidly progressive course.
Hepatorenal syndrome: a review
TLDR
The hepatorenal syndrome is a reversible functional acute renal failure secondary to intense renal cortical vasoconstriction in a patient with liver disease that characteristically has increased cardiac output, low arterial pressure, and reduced systemic vascular resistance.
Outcomes of liver transplantation in patients with hepatorenal syndrome.
TLDR
The appropriate use of SLKT in patients with HRS remains controversial and requires further evidence by the transplant community, and future studies identifying optimal vasoconstrictor regimens, alternative therapies, and factors predictive of response to therapy are needed.
Síndrome hepatorrenal Hepatorenal syndrome
TLDR
There are pharmacological strategies that can prevent the hepatorenal syndrome before transplantation in alcoholic cirrhosis and some clinical studies had evaluated the effectiveness of Pentoxifi line, albumin and noradrenalin, Octreotide or Terlipressin.
High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
TLDR
High age is a predictor of non-response in treatment response and overall mortality in patients with hepatorenal syndrome, and terlipressin and albumin co-treatment is associated with increased two-months survival rate.
Hot topics in liver intensive care.
TLDR
The present work seeks to provide an overview of the "hottest topics" among liver-related problems in intensive care, and terlipressin together with fluid and albumin substitution appear to be the most promising therapeutic interventions.
Cirrhotic Cardiomyopathy: Pathogenic Mechanisms and Management Strategies
TLDR
Current pharmacological treatment is nonspecific and directed towards alleviation of left ventricular failure, and Liver transplantation is currently the only proven treatment with a specific effect on cirrhotic cardiomyopathy.
Cardiac Output Changes in Hepatorenal Syndrome
TLDR
Patients with HCV related decompensated liver cirrhosis and hepatorenal syndrome have normal or high cardiac output values which seem to be insufficient to maintain adequate tissue perfusion.
Albumin Dialysis MARS: Knowledge from 10 Years of Clinical Investigation
TLDR
Together, albumin dialysis represents a valuable therapeutic tool for the treatment of various types of liver failure and ongoing and future studies will help define the optimal patient selection and technical process parameters such as session length and frequency of treatment.
Perioperative Evolution of Sodium Levels in Cirrhotic Patients Undergoing Liver Transplantation: An Observational Cohort and Literature Review
TLDR
Plasmatic sodium concentrations among hyponatremic cirrhotic patients undergoing OLT seem to reach normal levels after OLT and remain stable six months after surgery providing more evidence for the importance of sodium levels in prioritization of liver transplant candidates.
...
1
2
3
...

References

SHOWING 1-10 OF 68 REFERENCES
Hepatorenal Syndrome: A Dreaded Complication of End-Stage Liver Disease
  • A. Cárdenas
  • Medicine
    The American Journal of Gastroenterology
  • 2005
Hepatorenal syndrome is the dreaded complication of end-stage liver disease characterized by functional renal failure due to renal vasoconstriction in the absence of underlying kidney pathology. The
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.
TLDR
The current article is focused on the treatment of ascites and HRS in cirrhosis and the rationale of the therapeutic measures used in patients with cirrhotic patients with ascites or HRS is briefly reviewed.
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
TLDR
The decrease in effective arterial blood volume and the activation of vasoconstrictor systems play a crucial role in the pathogenesis of hepatorenal syndrome.
Hepatorenal syndrome—Is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?
  • K. Lenz
  • Medicine, Biology
    Hepatology
  • 2005
TLDR
Examining the systemic and hepatic circulation and the activity of various vasoactive systems in a group of 65 patients with cirrhosis and ascites finds those who developed HRS had a significantly higher hepatic venous pressure gradient (HVPG) and greater activity of RAAS, as well as noradrenaline concentrations (NE) compared with those who did not develop HRS in the follow-up period.
Circulatory function and hepatorenal syndrome in cirrhosis
TLDR
The data indicate that hepatorenal syndrome is the result of a decrease in cardiac output in the setting of a severe arterial vasodilation, and plasma renin activity and cardiac output were the only independent predictors of hepat Lorenal syndrome.
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome
TLDR
In conclusion, TIPS is an effective treatment for type 1 HRS in suitable patients with cirrhosis and ascites, following the improvement of renal function with combination therapy of midodrine, octreotide, and albumin.
Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
TLDR
Long-term terlipressin administration is safe and effective to control type 1 HRS, however, it does not cure the underlying disease and therefore, may only be considered as a bridge to a definitive treatment as liver transplantation.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial
  • S. Mitzner, J. Stange, +14 authors R. Schmidt
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2000
TLDR
It is concluded that the removal of albumin‐bound substances with the MARS method can contribute to the treatment of type I HRS.
Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine
TLDR
Evaluating the therapeutic potential of the vasoconstrictor ornipressin plus dopamine in the treatment of the most severe form of HRS type 1 found it can be a useful therapeutic option in patients with H RS type 1, especially as bridge to liver transplantation.
Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
TLDR
Terrlipressin and Gelatinepolysuccinat appear to be a safe and effective treatment of hepatorenal syndrome in a time period of six days.
...
1
2
3
4
5
...